Why the study?
Evidence on the real-world use and long-term effectiveness of PCSK9 inhibitors such as evolocumab in patients with familial hypercholesterolemia remained limited.
Population
2117 Japanese patients with familial hypercholesterolemia in the safety set, 1380 in the effectiveness analysis
Comparison
Heterozygous familial hypercholesterolemia vs homozygous familial hypercholesterolemia receiving evolocumab
Design
Postmarketing surveillance study
Follow-up
104 weeks
Answers are grounded in this paper and cite their sources.
Supports sustained LDL-C lowering in HeFH/HoFH; extends prior data but leaves open outcome trials before practice change.
BACKGROUND: Evidence on the real-world use of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in familial hypercholesterolemia (FH) remains limited. This postmarketing surveillance study (NCT02808403) evaluated Japanese patients with FH and the long-term real-world effectiveness of evolocumab. METHODS: This analysis included patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Diagnostic pathways, patient characteristics, background lipid-lowering therapy, evolocumab use, low-density lipoprotein cholesterol (LDL-C) reduction, long-term target achievement, and findings in pediatric HoFH were assessed. RESULTS: Of 2117 patients in the safety analysis set (HeFH, n=2009; HoFH, n=108), 1380 (HeFH, n=1296; HoFH, n=84) were included in the effectiveness analysis. Compared with patients with HeFH, patients with HoFH had higher genetic testing rates (40.7% versus 9.8%), higher mean baseline LDL-C levels (188.4±107.3 mg/dL versus 139.2±58.3 mg/dL), and higher lipoprotein apheresis use (26.9% versus 2.1%), but fewer total comorbidities (2.2±1.5 versus 2.7±1.5). Statin use was similarly high in patients with HeFH and HoFH (92.2% and 93.5%, respectively) with many patients receiving low- to moderate-intensity statins. Most patients received evolocumab biweekly. LDL-C reductions were evident at 4 weeks and sustained at 104 weeks. At 104 weeks, mean LDL-C changes from baseline were -54.0% in patients with HeFH and -48.9% in patients with HoFH. LDL-C<70 mg/dL was achieved by 63.0% of patients with HeFH and 43.9% of patients with HoFH, and LDL-C<55 mg/dL was achieved by 48.2% and 17.1%, respectively. CONCLUSION: Evolocumab was associated with sustained LDL-C reductions over 104 weeks in Japanese patients with HeFH and HoFH, with higher target achievement in HeFH. Gaps exist in genetic testing and treatment optimization in routine Japanese FH care.
No takes yet. Share an insight, caveat, or question.
Ogura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: